Research
Hormonal
MBS significantly reduces the risk of developing obesity-associated cancers and cancer-related mortality.
Undergoing MBS not only helps with weight but also significantly lowers your long-term risk of developing various cancers and dying from cancer compared to remaining obese.
GoodSupportsHIGH confidence
MBS reduces the risk of developing cancer in the population with class II/III obesity, ranging from 11% to 50% for all cancer types... MBS may significantly reduce overall cancer mortality compared with nonsurgical obese controls.
Why this rating
Based on large retrospective cohort studies and meta-analyses, though RCT data on cancer outcomes is limited.
Source
2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery
Dan Eisenberg et al. · Obesity Surgery · 2022
DOI 10.1007/s11695-022-06332-1
clinical_guidelineCited 627×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metabolic and bariatric surgery (MBS) is recommended for individuals with BMI >35 kg/m2 regardless of comorbidity status, and for those with BMI 30-34.9 kg/m2 who have metabolic disease or fail nonsurgical treatments.Strong
- MBS serves as an effective bridge to other specialty surgeries (joint arthroplasty, hernia repair, organ transplantation) by reducing surgical risks and complications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →